Company Filing History:
Years Active: 2015-2017
Title: Jie Yang: Innovator in GABAergic Receptor Research
Introduction
Jie Yang is a prominent inventor based in Rensselaer, NY (US). He has made significant contributions to the field of pharmacology, particularly in the development of GABAergic receptor subtype selective ligands. With a total of 2 patents, his work focuses on innovative solutions for treating various neurological disorders.
Latest Patents
Yang's latest patents include groundbreaking research on GABAergic receptor subtype selective ligands and their uses. These patents describe the development of α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, along with pharmaceutical compositions and methods for their application. The ligands are designed to treat anxiety disorders, epilepsy, and schizophrenia while minimizing sedative and ataxic side effects. Notably, these ligands lack ester linkages, making them relatively insensitive to hydrolysis by esterases, which enhances their therapeutic potential.
Career Highlights
Jie Yang is associated with the UWM Research Foundation, Inc., where he continues to advance his research. His work has garnered attention for its innovative approach to addressing complex neurological conditions. Yang's contributions are paving the way for new treatment options that could significantly improve patient outcomes.
Collaborations
Yang collaborates with esteemed colleagues, including James M. Cook and Terry S. Clayton. These partnerships enhance the research efforts and broaden the impact of their findings in the scientific community.
Conclusion
Jie Yang's innovative work in the field of GABAergic receptor research exemplifies the potential of targeted pharmacological treatments. His patents and collaborations reflect a commitment to advancing medical science and improving the lives of individuals affected by neurological disorders.